Clinical Trial

A Study of GC101 TIL in Advanced Melanoma

Study acronym: MIZAR-003
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
98 participants will be randomly assigned 1:1 to the experimental group and the control group for the Phase II clinical trial，this trail is expected to be finished in 24 months
Protocol Amendment History 2 changes
notable Primary completion moved earlier: 2026-07-10 -> 2026-05-12 2026-08-06
minor Completion pushed: 2026-12-20 -> 2027-12-20 2026-08-06
Trial Details
NCT Number NCT06703398
Lead Sponsor Shanghai Juncell Therapeutics
Conditions Melanoma
Enrollment 98 participants
Start Date 2024-12-20
Primary Completion 2026-05-12 (estimated)
Study Completion 2027-12-20 (estimated)
Updated on ClinicalTrials.gov 2026-08-05